8-K filing — INCYTE CORP (INCY)
Filed: 2026-11-13 AccNo: 0000879169-26-000068 Size: 135 KB Item 8.01: Other Events
Stocks · News reference
Natera and Incyte have entered into a clinical collaboration agreement to evaluate Incyte's investigational bispecific immunotherapy, INCA33890, in a new Phase II study for patients with stage 2/3 colorectal cancer.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-11-13 AccNo: 0000879169-26-000068 Size: 135 KB Item 8.01: Other Events
Incyte has selected the University of Maryland School of Medicine and the H. Lee Moffitt Cancer Center & Research Institute as the recipients of its 2026 Incyte Ingenuity Awards in GVHD.
Incyte's net sales guidance for Opzelura includes a one-time $246 million financial benefit resulting from a settlement with the Centers for Medicare and Medicaid Services (CMS).
Leerink Partners has revised its price target for Incyte Corporation from $154 to $150.
Incyte announced it will present new clinical data regarding its hematology portfolio at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition.